ArticleBlood advances2022

TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms.

Roman R Schimmer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.